ICMR-National AIDS Research Institute, Pune, Maharashtra, India.
Clinton Health Access Initiative, New Delhi, India.
PLoS One. 2019 Jan 17;14(1):e0210556. doi: 10.1371/journal.pone.0210556. eCollection 2019.
Hepatitis C virus (HCV) infection is a major contributor to morbidity and mortality worldwide. Early detection and curative treatment of HCV can reduce the risk of liver-related mortality and serve to prevent transmission of new infections. India is estimated to have about six million HCV infected individuals, most of whom are unaware of their infection status. Rapid diagnostic test kits (RDTs) could help identify HCV infected persons more expeditiously and thus availability of high performing, quality-assured RDTs is essential to scale-up HCV screening efforts. The present study was thus undertaken to evaluate the performance characteristics of five anti-HCV RDTs.
Five anti-HCV RDTs (Alere Truline, Flaviscreen, Advanced Quality, SD Bioline and OraQuick) were evaluated using two panels of known anti-HCV positive and negative samples; one characterized from Indian patient samples (n = 360) and other obtained from the US Centers for Disease Control and Prevention (CDC), Atlanta (n = 100). Sensitivity, specificity, inter-observer agreement, test validity and operational characteristics of RDTs were assessed.
The combined sensitivities across both panels for Alere Truline, Flaviscreen, Advanced Quality, SD Bioline and OraQuick RDTs were 99.4% (95%CI-96.6%-99.9%), 86.2% (95%CI-79.8%-91.1%), 96.2% (95%CI-91.9%-98.6%), 99.4% (95%CI-96.6%-99.9%) and 99.4% (95%CI-96.6%-99.9%) respectively. The overall specificities across both panels for all RDTs were 99.7%. The inter-observer agreement was 100% for Alere Truline, SD Bioline and OraQuick, while it was 99.5% and 98.6% with Advanced Quality and Flavicheck respectively. Discordant results were significantly associated with human immunodeficiency virus (HIV) positivity for both Advanced Quality and Flavicheck (p<0.001).
The present evaluation demonstrated that Alere Truline, SD Bioline and OraQuick RDTs had sensitivity and specificity in accordance with the acceptance criteria of the Drug Controller General, India, the national regulatory authority, had excellent inter-observer agreement and superior operational characteristics. Our findings suggest that certain HCV RDTs perform well and can be a useful tool in screening of HCV infections expeditiously.
丙型肝炎病毒(HCV)感染是全球发病率和死亡率的主要原因。早期发现和治愈 HCV 可以降低与肝脏相关的死亡率,并有助于预防新的感染。印度估计有大约 600 万 HCV 感染者,其中大多数人不知道自己的感染状况。快速诊断检测试剂盒(RDT)可以帮助更迅速地识别 HCV 感染者,因此,提供高性能、质量保证的 RDT 对于扩大 HCV 筛查工作至关重要。因此,进行了这项研究以评估五种抗 HCV RDT 的性能特征。
使用两个已知抗 HCV 阳性和阴性样本的面板评估了五种抗 HCV RDT(Alere Truline、Flaviscreen、Advanced Quality、SD Bioline 和 OraQuick);一个来自印度患者样本(n=360),另一个来自美国亚特兰大疾病控制和预防中心(CDC)(n=100)。评估了 RDT 的敏感性、特异性、观察者间一致性、测试有效性和操作特征。
Alere Truline、Flaviscreen、Advanced Quality、SD Bioline 和 OraQuick RDT 在两个面板中的综合敏感性分别为 99.4%(95%CI-96.6%-99.9%)、86.2%(95%CI-79.8%-91.1%)、96.2%(95%CI-91.9%-98.6%)、99.4%(95%CI-96.6%-99.9%)和 99.4%(95%CI-96.6%-99.9%)。所有 RDT 在两个面板中的总体特异性均为 99.7%。Alere Truline、SD Bioline 和 OraQuick 的观察者间一致性为 100%,而 Advanced Quality 和 Flavicheck 分别为 99.5%和 98.6%。对于 Advanced Quality 和 Flavicheck,不一致的结果与人类免疫缺陷病毒(HIV)阳性显著相关(p<0.001)。
本评估表明,Alere Truline、SD Bioline 和 OraQuick RDT 具有符合印度国家监管机构药品控制器总干事接受标准的敏感性和特异性,具有极好的观察者间一致性和卓越的操作特性。我们的研究结果表明,某些 HCV RDT 表现良好,可作为快速筛查 HCV 感染的有用工具。